SANOFI SAYS CO, GSK INTEND TO MAKE AVAILABLE 200 MLN DOSES OF ADJUVANTED RECOMBINANT PROTEIN-BASED COVID-19 VACCINE, IF APPROVED, TO COVAX FACILITY